Personalized Medicine Outsourcing Market Size, Share & Trends Report

Personalized Medicine Outsourcing Market (2025 - 2030) Size, Share & Trends Analysis Report By Phase (Preclinical, Clinical), By Application (Oncology, Rare Diseases), By Service, By Type, By End Use, By Region, And Segment Forecasts

Market Segmentation

Personalized Medicine Outsourcing Product Outlook (Revenue, USD Million, 2018 - 2030)
- Clinical
  - Phase I
  - Phase II
  - Phase III
  - Phase IV
- Preclinical
Personalized Medicine Outsourcing Application Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Rare Diseases
- Infectious Diseases
- Others
Personalized Medicine Outsourcing Service Outlook (Revenue, USD Million, 2018 - 2030)
- Contract Manufacturing
- Contact Development
Personalized Medicine Outsourcing Type Outlook (Revenue, USD Million, 2018 - 2030)
- Inhibitor Drugs
- Monoclonal Antibodies
- Cell & Gene Therapy
- Others
Personalized Medicine Outsourcing End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Personalized Medicine Outsourcing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
    - Clinical
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Preclinical
  - North America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Rare Diseases
    - Infectious Diseases
    - Others
  - North America Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Contract Manufacturing
    - Contact Development
  - North America Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Inhibitor Drugs
    - Monoclonal Antibodies
    - Cell & Gene Therapy
    - Others
  - North America End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical Companies
    - Biotechnology Companies
    - Others
  - U.S
    - U.S. Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - U.S. Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - U.S. Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - U.S. Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - U.S. End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Canada
    - Canada Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Canada Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Canada Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Canada Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Canada End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Mexico
    - Mexico Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Mexico Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Mexico Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Mexico Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Mexico End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
- Europe
  - Europe Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
    - Clinical
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Preclinical
  - Europe Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Rare Diseases
    - Infectious Diseases
    - Others
  - Europe Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Contract Manufacturing
    - Contact Development
  - Europe Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Inhibitor Drugs
    - Monoclonal Antibodies
    - Cell & Gene Therapy
    - Others
  - Europe End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical Companies
    - Biotechnology Companies
    - Others
  - Germany
    - Germany Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Germany Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Germany Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Germany Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Germany End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - UK
    - UK Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - UK Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - UK Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - UK Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - UK End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - France
    - France Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - France Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - France Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - France Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - France End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Italy
    - Italy Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Italy Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Italy Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Italy Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Italy End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Spain
    - Spain Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Spain. Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Spain Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Spain Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Spain End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Denmark
    - Denmark Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Denmark Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Denmark Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Denmark Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Denmark End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Sweden
    - Sweden Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Sweden Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Sweden Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Sweden Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Sweden End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Norway
    - Norway Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Norway Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Norway Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Norway Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Norway End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
- Asia Pacific
  - Asia Pacific Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
    - Clinical
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Preclinical
  - Asia Pacific Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Rare Diseases
    - Infectious Diseases
    - Others
  - Asia Pacific Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Contract Manufacturing
    - Contact Development
  - Asia Pacific Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Inhibitor Drugs
    - Monoclonal Antibodies
    - Cell & Gene Therapy
    - Others
  - Asia Pacific End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical Companies
    - Biotechnology Companies
    - Others
  - China
    - China Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - China Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - China Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - China Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - U.S. End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Japan
    - Japan Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Japan Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Japan Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Japan Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Japan End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - India
    - India Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - India Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - India Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - India Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - India. End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - South Korea
    - South Korea Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - South Korea Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - South Korea Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - South Korea Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - South Korea End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Australia
    - Australia Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Australia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Australia Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Australia Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Australia End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Thailand
    - Thailand Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Thailand Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Thailand Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Thailand Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Thailand End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
- Latin America
  - Latin America Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
    - Clinical
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Preclinical
  - Latin America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Rare Diseases
    - Infectious Diseases
    - Others
  - Latin America Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Contract Manufacturing
    - Contact Development
  - Latin America Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Inhibitor Drugs
    - Monoclonal Antibodies
    - Cell & Gene Therapy
    - Others
  - Latin America End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical Companies
    - Biotechnology Companies
    - Others
  - Brazil
    - Brazil Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Brazil Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Brazil Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Brazil Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Brazil End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Mexico
    - Mexico Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Mexico Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Mexico Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - MexicoType Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Mexico End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Argentina
    - Argentina Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Argentina Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Argentina Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Argentina Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - U.S. End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
- MEA
  - MEA Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
    - Clinical
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Preclinical
  - MEA Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Rare Diseases
    - Infectious Diseases
    - Others
  - MEA Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Contract Manufacturing
    - Contact Development
  - MEA Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Inhibitor Drugs
    - Monoclonal Antibodies
    - Cell & Gene Therapy
    - Others
  - MEA End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical Companies
    - Biotechnology Companies
    - Others
  - South Africa
    - South Africa Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - South Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - South Africa Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - South Africa Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - South Africa End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Saudi Arabia
    - Saudi Arabia Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Saudi Arabia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Saudi Arabia Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Saudi Arabia Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Saudi Arabia End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - UAE
    - UAE Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - UAE Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - UAE Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - UAE Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - UAE End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others
  - Kuwait
    - Kuwait Personalized Medicine Outsourcing Outlook (Revenue, USD Million, 2018 - 2030)
      - Clinical
        
        Phase I
        
        Phase II
        
        Phase III
        
        Phase IV
      - Preclinical
    - Kuwait Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Rare Diseases
      - Infectious Diseases
      - Others
    - Kuwait Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Contract Manufacturing
      - Contact Development
    - Kuwait Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Inhibitor Drugs
      - Monoclonal Antibodies
      - Cell & Gene Therapy
      - Others
    - Kuwait End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical Companies
      - Biotechnology Companies
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments